Breast Cancer

Researchers highlighted the importance of recognizing the environmental and biological factors that contribute to the development of PTSD, which can help inform clinical care and potentially reduce PTSD comorbidity.

The combination demonstrated a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of individuals with early triple-negative breast cancer, regardless of PD-L1 expression.

A recent study demonstrated the validity of current breast cancer testing panels for use in African American women and provides a basis for increased referral of this patient population for cancer genetic testing.

Payment models with shared-savings components, such as the Oncology Care Model, may be associated with fewer visits and lower costs in certain cancer settings in the first year.

A study found that a 6-month follow-up examination was recommended for women found to have BI-RADS 3 lesions after previous recommendations suggested a year follow-up was safely sufficient.

A recent examination of older adults with cancer found accelerated losses in differing sarcopenia measures existed before and after a cancer diagnosis.

An analysis of women in Sweden found that mammography screening reduces the rate of advanced and fatal breast cancers, regardless of changes in treatment regimens.

Insulin resistance was found to be 1 factor that contributes to the worse prognosis in breast cancer between black and white women, potentially through direct effects of insulin on the tumor insulin receptor.

Experts review the current landscape and potential use of neoadjuvant chemotherapy with additional novel agents for patients with localized TNBC.

This study analyzed the full prevalence and spectrum of partner and localizer BRCA2 (PALB2) germline mutations in China, focusing on the associations between these PALB2 germline mutations and breast cancer risk.

The results from this random-effects meta-analysis suggested that dietary fiber intake may decrease the risk of breast cancer, including both premenopausal and postmenopausal breast cancers.

A recent study led by led by King's College London and Public Health England examined 1.4 million patients of cancer via the National Cancer Registry and found that early GP referrals led to longer survival rates for patients.

The breast cancer expert discussed the implications of this approval, as well as the data that led to the approval of sacituzumab govitecan-hziy.

This study found a substantial difference in the number of agents available for use in the metastatic and adjuvant settings for non-small cell lung cancer, breast cancer, and colon cancer.

Brendan F. Kennedy, PhD, discussed this study which evaluated the accuracy of quantitative micro-elastography compared to optical coherence tomography.

The FDA granted a breakthrough therapy designation and priority review under its Accelerated Approval Program to sacituzumab govitecan-hziy for the treatment of patients with metastatic triple-negative breast cancer.

Identifying early predictors of poor quality of life could allow for the identification of patients who may benefit from early referral to palliative and supportive care according to the researchers.

A prognostic survival model, titled PROVIEW, was able to accurately predict changing cancer survival risk over time and may have the potential to be a useful prognostic tool that can be completed by patients.

The FDA approved tucatinib in combination with chemotherapy for the treatment of adult patients with advanced forms of HER2-positive breast cancer.

This study examined delayed targeted intraoperative radiotherapy vs external beam radiotherapy to determine how it impacted patients with breast cancer, finding no statically significant decrease in mastectomy-free survival, distant-disease survival or overall survival.

A group of expert medical societies developed joint recommendations for healthcare professionals and patients to guide the prioritization, treatment and triage of breast cancer during the COVID-19 pandemic.

Given that these features are associated with breast cancer risk and could improve the detection of short-term risk of breast cancer, the authors suggested that further investigation of common loci is necessary.

The decision to halt the study was based on the unanimous recommendation by an independent data safety monitoring committee during its routine review of the ASCENT study.

Experts provide perspective on the rapidly changing landscape of targeted therapies in breast cancer treatment, and the importance of matching the right agent with the right patient.

ONCOLOGY® recently sat down with Joyce A. O’Shaughnessy, MD, to discuss the recent trends in breast cancer treatment and the avalanche of agents moving through the development pipeline that have the potential to redefine the accepted standards of care.

CytoDyn announced that it has enrolled and treated the first 2 patients with COVID-19 with leronlimab under its phase II randomized clinical trial.

Plastic surgeon and breast specialist Dr. Constance Chen discussed the potential complications of implant-based breast reconstruction, and how it compares to natural tissue reconstruction.

Researchers reported on the incidence and outcomes of the SARS-CoV-2 infection, which has been linked to COVID-19, in patients with cancer who were treated at a tertiary cancer institution in Wuhan, China.

In this study, polypharmacy during the 6-month time period pre-IV chemotherapy was highly predictive of post-chemotherapy inpatient hospitalization.

This study examined the association of disease progression and the deterioration of health-related quality of life for patients with metastatic breast, pancreatic, lung, and colorectal cancer.